Our top pick for
Pacira BioSciences, Inc is a drug manufacturers-specialty & generic business based in the US. Pacira BioSciences shares (PCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pacira BioSciences employs 606 staff and has a trailing 12-month revenue of around USD$421.1 million.
|52-week range||USD$27.46 - USD$79.98|
|50-day moving average||USD$71.4709|
|200-day moving average||USD$62.2945|
|Wall St. target price||USD$74.15|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$2.931|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Pacira BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pacira BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pacira BioSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Pacira BioSciences shares trade at around 26x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Pacira BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$54.9 million.
The EBITDA is a measure of a Pacira BioSciences's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$421.1 million|
|Operating margin TTM||9.65%|
|Gross profit TTM||USD$242.2 million|
|Return on assets TTM||2.51%|
|Return on equity TTM||27.1%|
|Market capitalisation||USD$3.2 billion|
TTM: trailing 12 months
There are currently 6.2 million Pacira BioSciences shares held short by investors – that's known as Pacira BioSciences's "short interest". This figure is 5.3% down from 6.6 million last month.
There are a few different ways that this level of interest in shorting Pacira BioSciences shares can be evaluated.
Pacira BioSciences's "short interest ratio" (SIR) is the quantity of Pacira BioSciences shares currently shorted divided by the average quantity of Pacira BioSciences shares traded daily (recently around 589652.27272727). Pacira BioSciences's SIR currently stands at 10.56. In other words for every 100,000 Pacira BioSciences shares traded daily on the market, roughly 10560 shares are currently held short.
However Pacira BioSciences's short interest can also be evaluated against the total number of Pacira BioSciences shares, or, against the total number of tradable Pacira BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pacira BioSciences's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Pacira BioSciences shares in existence, roughly 140 shares are currently held short) or 0.2014% of the tradable shares (for every 100,000 tradable Pacira BioSciences shares, roughly 201 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Pacira BioSciences.
Find out more about how you can short Pacira BioSciences stock.
We're not expecting Pacira BioSciences to pay a dividend over the next 12 months.
Over the last 12 months, Pacira BioSciences's shares have ranged in value from as little as $27.46 up to $79.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacira BioSciences's is 1.1345. This would suggest that Pacira BioSciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.